Raanana, Israel, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announce today the appointment of Dr. Michal Meir, Senior Consultant at MedTech SME Ltd., as Senior Director of Regulatory and Clinical Affairs. The appointment was made as part of the Company's preparations towards its clinical trial for PL-14 that is expected to commence in 2025. Dr. Meir brings over a decade of experience in the medical device and pharmaceutical industries, with a proven track record in regulatory strategy, clinical affairs management and product developmen

Raanana, Israel, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announces today the appointment of Asaf Azulay, the Managing Director of Eurofins' Li-Med team, to its leadership as its VP of Regulatory Affairs and Quality Assurance (RA/QA). This strategic appointment reflects Polyrizon's ongoing commitment to maintaining the highest industry standards as it advances its pipeline of cutting-edge solutions. Asaf Azulay brings over 20 years of extensive experience in the medical devices industry, with expertise in leading quality teams and i

Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product's development path.  Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong local tolerability, a critical benchmark in the product development roadmap. The study was designed to assess local tolerance and tissue response following a 4-hour application of a formulation

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until October 6, 2025, to r

Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide. Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon's proprietary Capture and Contain™ (C&C) hydrogel technology, an innovative intranasal spray formulation designed to create a protective biological barrier against allergens and viruses. This initiative marks a crucial step forward in Pol

RAANANA, ISRAEL, April 01, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a biotech company specializing in innovative intranasal hydrogels, today announced the closing of its previously announce private placement  of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit. The offering consisted of the sale of 35,416,667 Ordinary Units (or Pre-Funded Units), each consisting of (i) one (1) Ordinary Share or Pre-Funded Warrant, and (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant. The offering price per Ordinary Unit was $0.48 (or $0.47999 for each Pre-Funded Unit, which

RAANANA, ISRAEL, March 31, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company"), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $17.0 million of Ordinary Shares and/or pre-funded and investor warrants at a price of $0.48 per Ordinary Unit. The offering consists of the sale of 35,416,667 Ordinary Units (or Pre-Funded Units), each consisting of (i) one (1) Ordinary Share or Pre-Funded Warrant, and (ii) one (1) Series A Warrant to purchase one (1) Ordinary Share per warrant. The offering price per Ordinary Unit is $0.48 (o

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) --  Polyrizon Ltd. (NASDAQ:PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced the structuring of its clinical strategy for PL-14, the Company's proprietary intranasal allergy blocker for seasonal allergic rhinitis. The clinical strategy was updated in preparation for a planned pre-submission meeting with the U.S. Food and Drug Administration (FDA), which is expected to be followed by the initiation of clinical trials. The comprehensive clinical studies is expected to include:

Raanana, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide. Many existing therapies fail to provide adequate control of acute repetitive seizures and may come with undesirable adverse e

Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind's psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ:CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, announced today that it has signed a non-binding Letter of Intent (LOI) with Polyrizon Ltd. (NASDAQ:PLRZ) ("Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, to develop a novel intranasal formulation for its psychedelic-

Raanana, Israel, March 14, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that it has signed a non-binding Letter of Intent (LOI) with a biotech company focused on psychedelic-derived therapeutics ("the psychedelic company"), to develop a novel intranasal formulation for psychedelic-based treatment applications. This agreement aims to leverage Polyrizon's proprietary platform to optimize the delivery of innovative psychedelic treatments for therapeutic use. This collaboration emphasizes the growing potential of intranasal drug deli

Raanana, Israel, March 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ:PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment. As previously announced, the study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development of intranasal and pulmonary drug delivery solutions and a member of the Company's Scientific Advisory Board. These preclinical

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

EFFECT - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

6-K - Polyrizon Ltd. (0001893645) (Filer)

POS AM - Polyrizon Ltd. (0001893645) (Filer)